alpha-VEGFR2-Fc (Saarland University)

alpha-VEGFR2-Fc is a recombinant fusion protein consisting of an anti-VEGFR2 (Vascular Endothelial Growth Factor Receptor 2) binding domain, typically a single-chain variable fragment (scFv), fused to an immunoglobulin Fc region. It is primarily utilized in preclinical research as a monospecific control or a targeting module for the development of multi-specific antibodies, such as bispecific T-cell engagers (bsAbs). In the context of tumor immunology, it is designed to target the tumor vasculature, where VEGFR2 is highly expressed on endothelial cells (ECs). While it can potentially inhibit VEGF-mediated signaling by binding to the receptor, its primary role in recent studies (such as those by Wadle et al.) is to serve as a comparative agent for bispecific constructs like anti-VEGFR2-anti-CD3. These studies demonstrate that while alpha-VEGFR2-Fc can bind to tumor ECs, it lacks the ability to activate anergic endothelial cells or promote T-cell infiltration unless combined with a T-cell engaging moiety.

Other names

anti-VEGFR2-Fc fusion proteinanti-VEGFR-2-Fc fusion proteinanti-VEGFR 2-Fc fusion proteinscFv-VEGFR2-FcscFv-VEGFR-2-FcscFv-VEGFR 2-Fc